The abstract is read at the publisher; the summary is JClub's.
mRNA/LNP delivery of COMP-Tie2* drives robust, persistent Tie2 autophosphorylation and Akt–FOXO1 signaling in pulmonary endothelial cells, exceeding COMP-Ang1 in strength and duration.
- Why it matters: Therapeutic Tie2 activation is limited by ligand instability, Ang2 competition, Tie2 ectodomain cleavage, VE-PTP dephosphorylation, and receptor degradation—especially during inflammatory diseases like ARDS or sepsis.
- What they did: The study engineered truncated, constitutively active, membrane-anchored Tie2 variants combining autoactivating kinase mutations with membrane-targeting domains, then delivered COMP-Tie2* via mRNA in lung-targeted lipid nanoparticles.
- The result: In vivo, systemic COMP-Tie2* mRNA produced selective pulmonary Tie2 receptor engagement, supporting a ligand-independent strategy for sustained endothelial stabilization under inflammatory conditions.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.